Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo

[1] Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39(Suppl 1): 7–18. KendallT VerheijJ GaudioE EvertM GuidoM GoeppertB CarpinoG Anatomical, histomorphological and molecular classification of cholangiocarcinoma Liver Int 2019 39 Suppl 1 7 18 Search in Google Scholar

[2] Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent intrahepatic cholangiocarcinoma–review. Front Oncol. 2021; 11:776863. doi: 10.3389/fonc.2021.776863 BekkiY Von AhrensD TakahashiH SchwartzM GunasekaranG Recurrent intrahepatic cholangiocarcinoma–review Front Oncol 2021 11 776863 10.3389/fonc.2021.776863 Open DOISearch in Google Scholar

[3] Yang Z, Shi G. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: a SEER population-based cohort study. Cancer Med. 2022; 11:692–704. YangZ ShiG Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: a SEER population-based cohort study Cancer Med 2022 11 692 704 Search in Google Scholar

[4] Cai C, Wang X, Fu Q, Chen A. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022; 20:40. doi: 10.1186/s12957-022-02511-7 CaiC WangX FuQ ChenA The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis World J Surg Oncol 2022 20 40 10.1186/s12957-022-02511-7 Open DOISearch in Google Scholar

[5] Jin W. ErBb family proteins in cholangiocarcinoma and clinical implications. J Clin Med. 2020; 9:2255. doi: 10.3390/jcm9072255 JinW ErBb family proteins in cholangiocarcinoma and clinical implications J Clin Med 2020 9 2255 10.3390/jcm9072255 Open DOISearch in Google Scholar

[6] Mancinelli R, Mammola CL, Sferra R, Pompili S, Vetuschi A, Pannarale L. Role of the angiogenic factors in cholangiocarcinoma. Appl Sci. 2019; 9:1393. doi: 10.3390/app9071393 MancinelliR MammolaCL SferraR PompiliS VetuschiA PannaraleL Role of the angiogenic factors in cholangiocarcinoma Appl Sci 2019 9 1393 10.3390/app9071393 Open DOISearch in Google Scholar

[7] Ma Z, Li H, Liu L. Combining PD-1 inhibitor with VEGF/VEGFR2 inhibitor in chemotherapy: report of a patient with end-stage cholangiocarcinoma and review of literature. Recent Pat Anticancer Drug Discov. 2021; 16:101–7. MaZ LiH LiuL Combining PD-1 inhibitor with VEGF/VEGFR2 inhibitor in chemotherapy: report of a patient with end-stage cholangiocarcinoma and review of literature Recent Pat Anticancer Drug Discov 2021 16 101 7 Search in Google Scholar

[8] Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019; 70:700–9. CadamuroM BrivioS MertensJ VismaraM MoncsekA MilaniC Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma J Hepatol 2019 70 700 9 Search in Google Scholar

[9] Liao W, Feng Q, Liu H, Du J, Chen X, Zeng Y. Circular RNAs in cholangiocarcinoma. Cancer Lett. 2022; 553:215980. doi: 10.1016/j.canlet.2022.215980 LiaoW FengQ LiuH DuJ ChenX ZengY Circular RNAs in cholangiocarcinoma Cancer Lett 2022 553 215980 10.1016/j.canlet.2022.215980 Open DOISearch in Google Scholar

[10] Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun. 2021; 27:100354. doi: 10.1016/j.ctarc.2021.100354 RizzoA BrandiG Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review Cancer Treat Res Commun 2021 27 100354 10.1016/j.ctarc.2021.100354 Open DOISearch in Google Scholar

[11] Yoh T, Hatano E, Seo S, Okuda Y, Fuji H, Ikeno Y, et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgery. World J Surg. 2018; 42:1848–56. YohT HatanoE SeoS OkudaY FujiH IkenoY Long-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgery World J Surg 2018 42 1848 56 Search in Google Scholar

[12] Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, Ravindra KV, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis. PLoS One. 2019; 14:e0220527. doi: 10.1371/journal.pone.0220527 MorisD KostakisID MachairasN ProdromidouA TsilimigrasDI RavindraKV Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis PLoS One 2019 14 e0220527 10.1371/journal.pone.0220527 Open DOISearch in Google Scholar

[13] Sarkis Y, Al Soueidy A, Kourie HR. Will advanced cholangiocarcinoma become a targetable malignancy? Crit Rev Oncol Hematol. 2021; 159:103233. doi: 10.1016/j.critrevonc.2021.103233 SarkisY Al SoueidyA KourieHR Will advanced cholangiocarcinoma become a targetable malignancy? Crit Rev Oncol Hematol 2021 159 103233 10.1016/j.critrevonc.2021.103233 Open DOISearch in Google Scholar

[14] Cai C, Wang X, Fu Q, Chen A. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022; 20:40. doi: 10.1186/s12957-022-02511-7 CaiC WangX FuQ ChenA The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis World J Surg Oncol 2022 20 40 10.1186/s12957-022-02511-7 Open DOISearch in Google Scholar

[15] Song F, Hu B, Cheng JW, Sun YF, Zhou KQ, Wang PX, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020; 11:573. doi: 10.1038/s41419-020-02749-7 SongF HuB ChengJW SunYF ZhouKQ WangPX Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma Cell Death Dis 2020 11 573 10.1038/s41419-020-02749-7 Open DOISearch in Google Scholar

[16] Pan S, Hu Y, Hu M, Xu Y, Chen M, Du C, et al. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NFκB pathway activation. Int J Oncol. 2020; 56:101–12. PanS HuY HuM XuY ChenM DuC S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NFκB pathway activation Int J Oncol 2020 56 101 12 Search in Google Scholar

[17] Takaya A, Yamamoto T, Tokoyoda K. Humoral immunity vs. Salmonella. Front Immunol. 2020; 10: 3155. doi: 10.3389/fimmu.2019.03155 TakayaA YamamotoT TokoyodaK Humoral immunity vs. Salmonella Front Immunol 2020 10 3155 10.3389/fimmu.2019.03155 Open DOISearch in Google Scholar

[18] Murakami T, Hiroshima Y, Miyake K, Kiyuna T, Endo I, Zhao M, Hoffman RM. Efficacy of tumor-targeting Salmonella typhimurium A1-R against malignancies in patient-derived orthotopic xenograft (PDOX) murine models. Cells. 2019; 8:599. doi: 10.3390/cells8060599 MurakamiT HiroshimaY MiyakeK KiyunaT EndoI ZhaoM HoffmanRM Efficacy of tumor-targeting Salmonella typhimurium A1-R against malignancies in patient-derived orthotopic xenograft (PDOX) murine models Cells 2019 8 599 10.3390/cells8060599 Open DOISearch in Google Scholar

[19] Zhao T, Guo M, Chen H, Zhou L, Guo J, Liu S, et al. IDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growth. Curr Mol Pharmacol. 2023; 16:881–93. ZhaoT GuoM ChenH ZhouL GuoJ LiuS IDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growth Curr Mol Pharmacol 2023 16 881 93 Search in Google Scholar

[20] Phan T, Nguyen VH, D’Alincourt MS, Manuel ER, Kaltcheva T, Tsai W, et al. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Ther. 2020; 27: 235–45. PhanT NguyenVH D’AlincourtMS ManuelER KaltchevaT TsaiW Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth Cancer Gene Ther 2020 27 235 45 Search in Google Scholar